7
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T61826 | NLRP3-IN-4 | ||
NLRP3-IN-4 is a highly efficient and orally bioavailable inhibitor of NLRP3 inflammasome, which exhibits strong anti-inflammatory properties specifically targeted towards colitis. | |||
T3230 | NLRP3-IN-2 | 5-Chloro-N-(p-sulfamoylphenethyl)-o-anisamide,NLRP3 Inflammasome Inhibitor I | NOD-like Receptor (NLR) , NOD |
NLRP3-IN-2 (5-Chloro-N-(p-sulfamoylphenethyl)-o-anisamide), an intermediate capable of synthesizing glibenclamide, exerts an inhibitory effect on the formation of NLRP3 inflammatory vesicles in cardiomyocytes, limiting i... | |||
T39552 | NLRP3-IN-5 | NLRP3-IN-5 | |
NLRP3-IN-5, a compound disclosed in WO2016131098, is an inhibitor of NLRP3 inflammasome. It consists of the chemical structure N-((4-chloro-2,6-dimethylphenyl)carbamoyl)-4-(2-hydroxypropan-2-l)furan-2-sulfonamide. | |||
T81666 | NLRP3-IN-22 | NOD-like Receptor (NLR) | |
NLRP3-IN-22 (Compound II-4) is an inhibitor of NLRP3, exhibiting a 67% inhibition rate at a concentration of 10 μM [1]. | |||
T60868 | NF-κB-IN-4 | ||
NF-κB-IN-4 (compound 17) is a potent inhibitor of NF-κB pathway which can cross blood brain barrier (BBB). NF-κB-IN-4 shows potential anti-neuroinflammatory activity with low toxicity which can be used for the research o... | |||
T81579 | P2X7 receptor antagonist-4 | ||
Compound 14a (P2X7 receptor antagonist-4) is a P2X7R antagonist with IC50 values of 64.7 nM in humans and 10.1 nM in mice. It inhibits the activation of the NLRP3 inflammasome, which subsequently reduces the expression o... | |||
T38106 | JC-171 | ||
JC-171, a selective inhibitor of the NLRP3 inflammasome, effectively inhibits LPS/ATP-induced interleukin-1β (IL-1β) release from J774A.1 macrophages with an IC50 of 8.45 μM[1]. |